Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heiko Jessen

Showing results (21-30 of 74) with videos related to

Pageof 8
Sort By:
AIDS (London, England)|October 18, 2005
Detection of minor populations of drug-resistant HIV-1 in acute seroconvertersKarin J Metzner, Pia Rauch, Hauke Walter, et al.
Plos One|May 3, 2014
First line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV-1 seroconverter studyFabia Zu Knyphausen, Ramona Scheufele, Claudia Kücherer, et al.
Sexually Transmitted Diseases|December 31, 2005
Understanding recent increases in the incidence of sexually transmitted infections in men having sex with men: changes in risk behavior from risk avoidance to risk reductionUlrich Marcus, Viviane Bremer, Osamah Hamouda, et al.
The Journal of Infection|November 5, 2005
Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patientsEsther Voigt, Christian Schulz, Gerd Klausen, et al.
Antimicrobial Agents and Chemotherapy|October 27, 2004
Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patientsHartmut Stocker, Guido Kruse, Peter Kreckel, et al.
Plos One|July 24, 2008
CCR5Delta32 genotypes in a German HIV-1 seroconverter cohort and report of HIV-1 infection in a CCR5Delta32 homozygous individualDjin-Ye Oh, Heiko Jessen, Claudia Kücherer, et al.
AIDS (London, England)|April 7, 2007
Loss of HIV-1-specific T-cell responses associated with very rapid HIV-1 disease progressionHendrik Streeck, Becky Schweighardt, Heiko Jessen, et al.
The Journal of Antimicrobial Chemotherapy|March 27, 2020
Five-year follow-up of patients enrolled in the NEAT 001/ANRS 143 randomized clinical trial: NEAT 001/ANRS 143 LONG TERM studyFrançois Raffi, Aurélie Gaultier, Anton Pozniak, et al.
Journal of Virology|July 17, 2015
Differential Ability of Primary HIV-1 Nef Isolates To Downregulate HIV-1 Entry ReceptorsMako Toyoda, Yoko Ogata, Macdonald Mahiti, et al.
AIDS (London, England)|April 20, 2004
Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjectsDaniel H Blanckenberg, Robin Wood, Andrzej Horban, et al.
Pageof 8

Showing results (21-30 of 74) with videos related to

Sort By:
Pageof 8
AIDS (London, England)|October 18, 2005
Detection of minor populations of drug-resistant HIV-1 in acute seroconvertersKarin J Metzner, Pia Rauch, Hauke Walter, et al.
Plos One|May 3, 2014
First line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV-1 seroconverter studyFabia Zu Knyphausen, Ramona Scheufele, Claudia Kücherer, et al.
Sexually Transmitted Diseases|December 31, 2005
Understanding recent increases in the incidence of sexually transmitted infections in men having sex with men: changes in risk behavior from risk avoidance to risk reductionUlrich Marcus, Viviane Bremer, Osamah Hamouda, et al.
The Journal of Infection|November 5, 2005
Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patientsEsther Voigt, Christian Schulz, Gerd Klausen, et al.
Antimicrobial Agents and Chemotherapy|October 27, 2004
Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patientsHartmut Stocker, Guido Kruse, Peter Kreckel, et al.
Plos One|July 24, 2008
CCR5Delta32 genotypes in a German HIV-1 seroconverter cohort and report of HIV-1 infection in a CCR5Delta32 homozygous individualDjin-Ye Oh, Heiko Jessen, Claudia Kücherer, et al.
AIDS (London, England)|April 7, 2007
Loss of HIV-1-specific T-cell responses associated with very rapid HIV-1 disease progressionHendrik Streeck, Becky Schweighardt, Heiko Jessen, et al.
The Journal of Antimicrobial Chemotherapy|March 27, 2020
Five-year follow-up of patients enrolled in the NEAT 001/ANRS 143 randomized clinical trial: NEAT 001/ANRS 143 LONG TERM studyFrançois Raffi, Aurélie Gaultier, Anton Pozniak, et al.
Journal of Virology|July 17, 2015
Differential Ability of Primary HIV-1 Nef Isolates To Downregulate HIV-1 Entry ReceptorsMako Toyoda, Yoko Ogata, Macdonald Mahiti, et al.
AIDS (London, England)|April 20, 2004
Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjectsDaniel H Blanckenberg, Robin Wood, Andrzej Horban, et al.
Pageof 8